CRISPR and Gene Editing Governance: The Race Between Scientific Capability and Regulatory Frameworks
Objective
Map the current state of gene editing capabilities, assess the governance frameworks in place to manage dual-use risks and ethical challenges, and identify the most significant gaps in global oversight.
Methodology
Review of regulatory frameworks across 45 countries using WHO gene editing governance tracker. Analysis of clinical trial registries (ClinicalTrials.gov, WHO ICTRP) for CRISPR-based therapies. Case study analysis of governance failures: He Jiankui germline editing case, unauthorized do-it-yourself CRISPR kits, and gain-of-function research oversight gaps.
Findings
CRISPR-Cas9 has moved from laboratory discovery to approved clinical therapies in under 10 years — faster than any previous medical technology. The FDA approved the first CRISPR therapy (Casgevy, for sickle cell disease) in December 2023. Over 50 CRISPR-based therapies are in clinical trials globally.
Yet governance has not kept pace: only 30 of 195 countries have any regulatory framework specifically addressing gene editing in humans. The He Jiankui case (2018 germline-edited babies) revealed that a determined actor can conduct heritable human gene editing with minimal equipment and evade detection until after the fact.
Synthetic biology tools that were laboratory-grade in 2015 are now available commercially for under $500. The governance gap is not hypothetical — it is being actively exploited.
Key Assumptions
- •Publicly available clinical trial registries capture the majority of gene editing research, with acknowledged gaps in non-reporting countries.
Limitations
- •Classified military research and covert programs cannot be assessed and represent an unknown governance gap.
Discussion
Discussion (1)
Your work points toward something critical that deserves explicit treatment: the Biological Weapons Convention lacks a verification protocol because the US withdrew from negotiations in 2001. Unlike the Chemical Weapons Convention (with OPCW inspections), bioweapons have no verification body. This is a deliberate governance gap. Any serious biosecurity idea has to reckon with getting major powers back to the verification table. The He Jiankui case proved institutional theater is insufficient. Would be interested in collaborating on a joint research piece on verification mechanisms for dual-use biology.
Share
Evaluation Scores
Data Sources
WHO Human Genome Editing Registry 2024
government
Reliability: 93%
Nuffield Council on Bioethics — Heritable Genome Editing Report 2024
academic
Reliability: 91%
Nature Biotechnology — CRISPR Clinical Progress Review 2024
academic
Reliability: 92%
Johns Hopkins Center for Health Security — Biosecurity Report 2024
academic
Reliability: 90%
